Regulation of BRCA-dependent Genome Repair via the 53BP1 Axis

ABSTRACT DNA double-strand breaks (DSB)s occur upon exposure of cells to ionizing radiation and chemicals in the environment, and when DNA replication forks become impeded by lesions and obstacles then subsequently collapse. Two mechanistically distinct DSB repair pathways, namely, homology-directed

repair (HDR) and non-homologous DNA end-joining (NHEJ), are responsible for the removal of the majority of DSBs. Whereas HDR is mostly accurate, NHEJ, while efficient, often entails loss of DNA sequence during repair, and can also generate chromosome translocations and replication fork fusions. Failure of

NHEJ or HDR leads to heightened engagement of alternate end-joining (AltEJ) and single-strand annealing (SSA), highly mutagenic and otherwise minor pathways, as repair tools. As such, the choice of DSB repair pathway has a major impact on the maintenance of genome stability, preventing neoplastic transformation

of cells, and oncogenesis. Our Program Project brings together seven leading NIH-funded laboratories within a highly collaborative and synergistic realm to delineate the mechanisms of HDR and replication fork maintenance, and how HDR is negatively regulated to favor the use of NHEJ as DSB repair tool. We have

assembled three Shared Resource Cores to provide state-of-the-art services in the production of high quality protein preparations for mechanistic experiments, biophysical and structural analyses of protein- ligand interactions and precise measurement of binding constants, and also cellular analyses of DSB repair

and replication fork maintenance. Altogether, we are exceptionally well poised to leverage our deep knowledge of DSB repair mechanisms and leadership to understand how the tumor suppressors BRCA1- BARD1 and BRCA2 function to promote HDR and to overcome the HDR restrictive action of the epigenetic mark reader 53BP1 and its associated factors such as DYNLL1 and the hetero-trimeric CTC1-STN1-TEN1

complex. As such, our Program Project will not only exert a major impact in elucidating mechanisms of DSB repair pathway choice and cancer drug resistance, but will also identify novel targets and pathways pivot points to guide the development of new therapeutic strategies to treat incalcitrant breast, ovarian and

other cancers.